Cencora, Inc. $COR Shares Bought by Nvwm LLC

Nvwm LLC raised its holdings in Cencora, Inc. (NYSE:COR) by 44,950.0% during the third quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor owned 2,703 shares of the company’s stock after purchasing an additional 2,697 shares during the period. Nvwm LLC’s holdings in Cencora were worth $812,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds also recently made changes to their positions in the business. Deutsche Bank AG bought a new position in shares of Cencora during the second quarter worth about $286,673,000. ExodusPoint Capital Management LP bought a new stake in Cencora in the fourth quarter valued at about $16,487,000. Impact Partnership Wealth LLC bought a new stake in Cencora in the first quarter valued at about $1,170,000. SEB Asset Management AB bought a new stake in Cencora in the first quarter valued at about $134,139,000. Finally, Wedge Capital Management L L P NC raised its stake in Cencora by 31.0% during the second quarter. Wedge Capital Management L L P NC now owns 105,614 shares of the company’s stock valued at $29,887,000 after buying an additional 24,968 shares in the last quarter. 97.52% of the stock is currently owned by hedge funds and other institutional investors.

Cencora Stock Performance

COR stock opened at $335.85 on Thursday. Cencora, Inc. has a 1 year low of $244.82 and a 1 year high of $377.54. The stock has a market capitalization of $64.09 billion, a price-to-earnings ratio of 24.95, a PEG ratio of 1.69 and a beta of 0.58. The company has a debt-to-equity ratio of 3.53, a quick ratio of 0.58 and a current ratio of 0.93. The stock’s fifty day moving average is $319.66 and its two-hundred day moving average is $302.88.

Cencora (NYSE:COR) last released its quarterly earnings results on Wednesday, August 5th. The company reported $4.48 EPS for the quarter, topping the consensus estimate of $4.35 by $0.13. Cencora had a net margin of 0.79% and a return on equity of 125.45%. The business had revenue of $84.75 billion during the quarter, compared to analyst estimates of $84.31 billion. During the same quarter in the prior year, the firm earned $4.00 earnings per share. The company’s quarterly revenue was up 5.1% on a year-over-year basis. On average, research analysts predict that Cencora, Inc. will post 17.87 EPS for the current year.

Cencora Dividend Announcement

The company also recently announced a quarterly dividend, which was paid on Monday, August 31st. Shareholders of record on Friday, August 14th were paid a dividend of $0.60 per share. This represents a $2.40 dividend on an annualized basis and a yield of 0.7%. The ex-dividend date of this dividend was Friday, August 14th. Cencora’s payout ratio is presently 17.83%.

Analyst Upgrades and Downgrades

A number of research firms have commented on COR. Royal Bank Of Canada reaffirmed a “sector perform” rating and set a $330.00 target price on shares of Cencora in a report on Tuesday, September 8th. Argus dropped their price target on Cencora to $340.00 and set a “buy” rating on the stock in a research report on Tuesday, June 23rd. Morgan Stanley upped their price target on Cencora from $342.00 to $346.00 and gave the company an “overweight” rating in a research report on Friday, August 7th. Citigroup restated a “buy” rating on shares of Cencora in a research note on Thursday, August 6th. Finally, Robert W. Baird lifted their price objective on shares of Cencora from $370.00 to $373.00 and gave the stock an “outperform” rating in a report on Monday. Fourteen research analysts have rated the stock with a Buy rating and four have issued a Hold rating to the company. Based on data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and a consensus price target of $365.69.

Insider Transactions at Cencora

In other Cencora news, EVP Elizabeth Campbell sold 11,300 shares of the company’s stock in a transaction dated Monday, August 24th. The shares were sold at an average price of $324.12, for a total value of $3,662,556.00. Following the completion of the transaction, the executive vice president owned 19,455 shares in the company, valued at approximately $6,305,754.60. This represents a 36.74% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. 0.38% of the stock is owned by insiders.

About Cencora

Cencora, formerly known as AmerisourceBergen, is a global pharmaceutical solutions company that sources, distributes and supports the delivery of medicines and healthcare products. The company serves pharmaceutical manufacturers, healthcare providers, pharmacies and animal-health customers through its supply-chain and commercialization services.

Its activities include pharmaceutical and specialty-product distribution, manufacturer services, specialty logistics, clinical-trial support, patient-support programs and other services designed to help bring medicines to market and improve access to treatment.